]> C16.1 Fundus of stomach C16.2 Body of stomach C16.3 Gastric antrum C16.4 Pylorus C16.5 Lesser curvature of stomach, NOS C16.6 Greater curvature of stomach, NOS C16.8 Overlapping lesion of stomach C16.9 Stomach, NOS &commontumorsizestomach; CS Extension Note 1: Intraluminal or intramural extension to esophagus and duodenum is classified by the depth of greatest invasion in any of these sites, including stomach. (For extension to esophagus or duodenum via serosa, see code 600.) Note 2: If the diagnosis states linitis plastica and no other information regarding extension is available, use code 350. Linitis plastic is defined as diffuse involvement of the entire thickness of the stomach wall. Note 3: Codes 610, 650, and 700 are for contiguous extension from the site of origin. Discontinuous involvement is coded in CS Mets at DX, except for implants within the stomach (code 300). Malignant (positive) peritoneal cytology is coded in CS Mets at DX. Code Description TNM 7 Map TNM 6 Map SS77 Map SS2000 Map 000 In situ, intraepithelial, noninvasive Tis Tis IS IS 050 (Adeno)carcinoma, noninvasive, in a polyp Tis Tis IS IS 100 Invasive tumor confined to mucosa, NOS, including intramucosal, NOS T1a T1 L L 110 Invades lamina propria T1a T1 L L 120 Invades muscularis mucosae T1a T1 L L 122 Mucosal tumor with intraluminal extension to esophagus or duodenum T1a T1 RE L 125 Stated as T1a with no other information on extension T1a T1 L L 130 T1NOS T1 L L 140 Confined to stalk of polyp T1NOS T1 L L 150 Tumor in polyp, NOS T1NOS T1 L L 160 Invades submucosa (superficial invasion) T1b T1 L L 165 Submucosal tumor with intraluminal extension to esophagus or duodenum T1b T1 RE L 170 Stated as T1b with no other information on extension T1b T1 L L 180 Stated as T1 [NOS] with no other information on extension T1NOS T1 L L 200 Invades into but not through muscularis propria T2 T2a L L 300 T1NOS T1 L L 340 ERROR ERROR ERROR ERROR 350 T2 T2a RE L 360 Invasion of muscularis propria with intraluminal extension to esophagus or duodenum T2 T2a RE L 390 Stated as T2 with no other information on extension T2 T2NOS L L 400 T3 T2b L L 415 Invasion through muscularis propria with intraluminal extension to esophagus or duodenum T3 T2b RE L 450 T3 T2b RE RE 480 Stated as T3 with no other information on extension T3 T2b L L 490 ERROR ERROR ERROR ERROR 500 T4a T3 RE RE 505 T4a T3 RE RE 550 ERROR ERROR ERROR ERROR 551 505 + 450 T4a T3 RE RE 555 Stated as T4a with no other information on extension T4a T3 RE RE 600 T4b T4 RE RE 610 T4b T4 RE RE 650 T4b T4 D D 690 ERROR ERROR ERROR ERROR 700 T4b T4 D D 800 Further contiguous extension T4b T4 D D 805 Stated as T4b with no other information on extension T4b T4 D D 810 Stated as T4 [NOS] with no other information on extension T4NOS T4 D D 950 No evidence of primary tumor T0 T0 U U 999 TX TX U U &generalcstsexteval; CS Lymph Nodes Note 1: Code only regional nodes and nodes, NOS in this field. Distant nodes are coded in CS Mets at DX. Note 2: Metastatic nodules in the fat adjacent to a gastric carcinoma, without evidence of residual lymph node tissue, are considered regional node metastases, but nodules implanted on peritoneal surfaces are considered distant metastases. Note 3: Hepatoduodenal nodes are regional for primaries of the lesser curvature of the stomach. They are coded in CS Mets at DX for all other subsites in this schema. Note 4: The number of positive regional nodes is required to calculate the correct N category for this schema. Use codes 610-750 when the pathology report assigns an N1, N2, or N3 category but does not specify the number of nodes involved, or the record identifies an N1, N2, or N3 category but the specific information about number of nodes involved is not available. Use codes 110-500 when information about the number of positive nodes is available, or when nodes are clinically positive but not removed for examination. Code Description TNM 7 Map TNM 6 Map SS77 Map SS2000 Map 000 No regional lymph node involvement N0 N0 NONE NONE 100 ^ * RN RN 110 ^ * RN RN 400 ^ * D RN 420 ^ * D D 500 Regional lymph node(s), NOS ^ * RN RN 600 N1 N1 RN RN 610 N1 N1 D RN 650 N2 N2 RN RN 660 N2 N1 RN RN 700 N3NOS N2 RN RN 710 Stated as pathologic N3a with no other information on regional lymph nodes N3a N2 RN RN 720 Stated as pathologic N3b with no other information on regional lymph nodes N3b N3 RN RN 750 N3NOS N2 RN RN 800 Lymph nodes, NOS N1 N1 RN RN 999 NX NX U U ^ For CS Lymph Nodes codes 100-500 and 800 ONLY, when CS Lymph Nodes Eval is 0, 1, 5, or 9, the N category is assigned from the Lymph Nodes Clinical Evaluation AJCC 7 Table, using Regional Nodes Positive and CS Site-Specific Factor 1; when CS Lymph Nodes Eval is 2, 3, 6, 8, or not coded, the N category is determined from the Lymph Nodes Pathologic Evaluation AJCC 7 Table Also Used When CS Reg Nodes Eval Is Not Coded using Regional Nodes Positive. * For CS Lymph Nodes codes 100-500 and 800 ONLY, when CS Lymph Nodes Eval is 0, 1, 5, or 9, the N category is assigned from the Lymph Nodes Clinical Evaluation AJCC 6 Table, using Regional Nodes Positive and CS Site-Specific Factor 1; when CS Lymph Nodes Eval is 2, 3, 6, 8, or not coded, the N category is determined from the Lymph Nodes Pathologic Evaluation AJCC 6 Table Also Used When CS Reg Nodes Eval Is Not Coded using Regional Nodes Positive. &generalregnodeseval; &commonreglnposcolon; &generalreglnexam; CS Mets at DX Code Description TNM 7 Map TNM 6 Map SS77 Map SS2000 Map 00 No distant metastasis M0 M0 NONE NONE 10 M1 M1 D D 40 M1 M1 D D 50 M1 M1 D D 60 M1 M1 D D 99 M0 MX U U &generalmetseval; CS Site-Specific Factor 1 Clinical Assessment of Regional Lymph Nodes Note 1: Only include information from imaging and physical examination in this item. Do not include information on regional lymph nodes that is based on surgical observation or diagnostic lymph node biopsy. Note 2: In the rare instance that the number of clinically positive regional nodes is stated but a clinical N category is not stated, use the code that reflects the most specific statement about the number of involved regional nodes. Note 3: If there is no diagnostic work-up to assess regional lymph nodes, use code 999. Do not apply the inaccessible nodes rule that presumes unmentioned nodes to be negative. Code Description 000 Nodes not clinically evident; imaging of regional nodes performed and nodes not mentioned 100 200 300 310 320 400 Clinically positive regional node(s), NOS 888 988 999 Regional lymph nodes involved pathologically, clinical assessment not stated Unknown if regional lymph nodes clinically evident Not documented in patient record CS Site-Specific Factor 2 Specific Location of Tumor Code Description 010 Fundus - Anterior Wall 020 Fundus - Posterior Wall 030 Fundus, NOS 040 Body - Anterior Wall 050 Body - Posterior Wall 060 Body - Lesser Curvature 070 Body - Greater Curvature 080 Body, NOS 090 Antrum - Anterior Wall 100 Antrum - Posterior Wall 110 Antrum - Lesser Curvature 120 Antrum - Greater Curvature 130 Antrum, NOS 140 Pylorus 150 Overlapping Lesion Anterior wall of stomach, NOS Posterior wall of stomach, NOS 160 Lesser curvature, NOS Medial curvature, NOS 170 Greater curvature, NOS Lateral curvature, NOS 888 988 999 ¬appssfactor3; ¬appssfactor4; ¬appssfactor5; ¬appssfactor6; ¬appnewssf7; ¬appnewssf8; ¬appnewssf9; ¬appnewssf10; ¬appnewssf11; ¬appnewssf12; CS Site-Specific Factor 13 Carcinoembryonic Antigen (CEA) Note: Record the interpretation of the highest CEA test results documented in the medical record prior to treatment. The interpretation should be for the same laboratory test recorded in CS Site-Specific Factor 14. Code Description 000 010 Positive/elevated 020 Negative/normal; within normal limits 030 Borderline; undetermined whether positive or negative 988 Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code 988 may result in an edit error.) 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 14 Carcinoembryonic Antigen (CEA) Lab Value Note 1: Carcinoembryonic antigen (CEA) is a tumor marker that has value in the management of certain malignancies. Note 2: The same laboratory test should be used to record information in CS Site-Specific Factors 1 and 3. Note 3: Record, to the nearest tenth of a nanogram/milliliter (ng/ml), the highest CEA lab value documented in the medical record prior to treatment. For example, a pretreatment CEA of 7 ng/ml would be recorded as 070. Note 4: Code 000 is reserved for exactly 0.0 ng/ml (no measurable amount of CEA). Do not round tiny values down to 0.0 ng/ml; any measured value less than or equal to 0.1 ng/ml should be coded 001. For code 001, also round 0.11-0.14 ng/ml down to 0.1 ng/ml. For codes 002-980, round values to the nearest tenth of a ng/ml. Note 5: For an uncertain value, record the stated closest value. For example, code a value stated as "less than 0.5 ng/ml" as 005. Code Description 000 0.0 nanograms/milliliter (ng/ml) exactly 001 002-979 980 98.0 or greater ng/ml 988 997 Tests ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 15 Carbohydrate Antigen 19-9 (CA 19-9) Lab Value Note 1: Carbohydrate Antigen 19-9 (CA 19-9) is a tumor marker that has value in the management of certain malignancies. Note 2: Record, to the nearest tenth of in Unit/milliliter (U/ml), the highest CA 19-9 lab value recorded in the medical record prior to treatment. Example: A pretreatment CA 19-9 of 60.0 U/mL would be recorded as 600. Note 3: Code 000 is reserved for exactly 0.0 U/mL (no measurable amount of CA 19 9). Do not round tiny values down to 0.0 U/mL; any measured value less than or equal to 0.1 U/mL should be coded 001. For code 001, also round 0.11-0.14 U/mL down to 0.1 U/mL. For codes 002-980, round values to the nearest tenth of a U/ml. Note 4: Use code 997 if an interpretation is documented but the actual lab value is not available in the record. Code Description 000 0.0 Units/milliter (U/ml) exactly 001 002-979 980 98.0 or greater U/ml 988 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 ¬appnewssf16; ¬appnewssf17; ¬appnewssf18; ¬appnewssf19; ¬appnewssf20; ¬appnewssf21; ¬appnewssf22; ¬appnewssf23; ¬appnewssf24; &commonssf25stomach; &commonhistinclusionstomach; &commonhistologyexclusions1; AJCC TNM 7 Stage T N M Stage T0 N0 M0 ERROR T0 N1 M0 UNK T0 N2 M0 UNK T0 N3a M0 UNK T0 N3b M0 UNK T0 N3NOS M0 UNK T0 NX M0 UNK Tis N0 M0 0 Tis N1 M0 ERROR Tis N2 M0 ERROR Tis N3a M0 ERROR Tis N3b M0 ERROR Tis N3NOS M0 ERROR Tis NX M0 0 T1a N0 M0 IA T1a N1 M0 IB T1a N2 M0 IIA T1a N3a M0 IIB T1a N3b M0 IIB T1a N3NOS M0 IIB T1a NX M0 UNK T1b N0 M0 IA T1b N1 M0 IB T1b N2 M0 IIA T1b N3a M0 IIB T1b N3b M0 IIB T1b N3NOS M0 IIB T1b NX M0 UNK T1NOS N0 M0 IA T1NOS N1 M0 IB T1NOS N2 M0 IIA T1NOS N3a M0 IIB T1NOS N3b M0 IIB T1NOS N3NOS M0 IIB T1NOS NX M0 UNK T2 N0 M0 IB T2 N1 M0 IIA T2 N2 M0 IIB T2 N3a M0 IIIA T2 N3b M0 IIIA T2 N3NOS M0 IIIA T2 NX M0 UNK T3 N0 M0 IIA T3 N1 M0 IIB T3 N2 M0 IIIA T3 N3a M0 IIIB T3 N3b M0 IIIB T3 N3NOS M0 IIIB T3 NX M0 UNK T4a N0 M0 IIB T4a N1 M0 IIIA T4a N2 M0 IIIB T4a N3a M0 IIIC T4a N3b M0 IIIC T4a N3NOS M0 IIIC T4a NX M0 UNK T4b N0 M0 IIIB T4b N1 M0 IIIB T4b N2 M0 IIIC T4b N3a M0 IIIC T4b N3b M0 IIIC T4b N3NOS M0 IIIC T4b NX M0 IIINOS T4NOS N0 M0 IIB T4NOS N1 M0 IIIA T4NOS N2 M0 IIINOS T4NOS N3a M0 IIIC T4NOS N3b M0 IIIC T4NOS N3NOS M0 IIIC T4NOS NX M0 UNK TX N0 M0 UNK TX N1 M0 UNK TX N2 M0 UNK TX N3a M0 UNK TX N3b M0 UNK TX N3NOS M0 UNK TX NX M0 UNK T0 N0 M1 IV T0 N1 M1 IV T0 N2 M1 IV T0 N3a M1 IV T0 N3b M1 IV T0 N3NOS M1 IV T0 NX M1 IV Tis N0 M1 ERROR Tis N1 M1 ERROR Tis N2 M1 ERROR Tis N3a M1 ERROR Tis N3b M1 ERROR Tis N3NOS M1 ERROR Tis NX M1 ERROR T1a N0 M1 IV T1a N1 M1 IV T1a N2 M1 IV T1a N3a M1 IV T1a N3b M1 IV T1a N3NOS M1 IV T1a NX M1 IV T1b N0 M1 IV T1b N1 M1 IV T1b N2 M1 IV T1b N3a M1 IV T1b N3b M1 IV T1b N3NOS M1 IV T1b NX M1 IV T1NOS N0 M1 IV T1NOS N1 M1 IV T1NOS N2 M1 IV T1NOS N3a M1 IV T1NOS N3b M1 IV T1NOS N3NOS M1 IV T1NOS NX M1 IV T2 N0 M1 IV T2 N1 M1 IV T2 N2 M1 IV T2 N3a M1 IV T2 N3b M1 IV T2 N3NOS M1 IV T2 NX M1 IV T3 N0 M1 IV T3 N1 M1 IV T3 N2 M1 IV T3 N3a M1 IV T3 N3b M1 IV T3 N3NOS M1 IV T3 NX M1 IV T4a N0 M1 IV T4a N1 M1 IV T4a N2 M1 IV T4a N3a M1 IV T4a N3b M1 IV T4a N3NOS M1 IV T4a NX M1 IV T4b N0 M1 IV T4b N1 M1 IV T4b N2 M1 IV T4b N3a M1 IV T4b N3b M1 IV T4b N3NOS M1 IV T4b NX M1 IV T4NOS N0 M1 IV T4NOS N1 M1 IV T4NOS N2 M1 IV T4NOS N3a M1 IV T4NOS N3b M1 IV T4NOS N3NOS M1 IV T4NOS NX M1 IV TX N0 M1 IV TX N1 M1 IV TX N2 M1 IV TX N3a M1 IV TX N3b M1 IV TX N3NOS M1 IV TX NX M1 IV &commonstagestomach; &commonsummarystage; Lymph Nodes Clinical Evaluation AJCC 7 Table Note: This table is used when CS Lymph Nodes is 100-500 and CS Lymph Nodes Eval is 0, 1, 5, or 9. The N category is determined based on the number of positive regional nodes in Regional Nodes Positive and the value of CS Site-Specific Factor 1, Clinical Assessment of Regional Lymph Nodes. Regional Nodes Positive CS SSF 1 000-100 0 100 CS SSF 1 200 200 CS SSF 1 300 300 CS SSF 1 310 310 CS SSF 1 320 320 CS SSF 1 400 400 CS SSF 1 888 888 CS SSF 1 988 988 CS SSF 1 999 999 00-00 N1 N2 N3NOS N3a N3b N1 ERROR ERROR N1 01-02 N1 N2 N3NOS N3a N3b N1 ERROR ERROR N1 03-06 N2 N2 N3NOS N3a N3b N2 ERROR ERROR N2 07-15 N3a N3a N3a N3b N3a N3a ERROR ERROR N3a 16-90 N3b N3b N3b N3b N3b N3b ERROR ERROR N3b 95-97 N1 N2 N3NOS N3a N3b N1 ERROR ERROR N1 98-99 N1 N2 N3NOS N3a N3b N1 ERROR ERROR N1 Lymph Nodes Pathologic Evaluation AJCC 7 Table Also Used When CS Reg Nodes Eval is Not Coded Note: This table is used when CS Lymph Nodes is 100-500 and CS Lymph Nodes Eval is 2, 3, 6, 8, or not coded. The N category is determined based on the number of positive regional nodes in Regional Nodes Positive. Regional Nodes Positive N Category 00-02 N1 03-06 N2 07-15 N3a 16-90 N3b 95-99 N1 &commonextralymphnodesclinicalevalstomach; &commonextralymphnodespathologicevalstomach;